| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8221956 | International Journal of Radiation Oncology*Biology*Physics | 2013 | 6 Pages |
Abstract
Neoadjuvant RT is feasible with moderate urinary morbidity. However, oncologic outcomes do not seem to be substantially different from those with selective postoperative RT. If this multimodal approach is further evaluated in a phase 2 setting, 54 Gy should be used in combination with neoadjuvant androgen deprivation therapy to improve biochemical outcomes.
Related Topics
Physical Sciences and Engineering
Physics and Astronomy
Radiation
Authors
Bridget F. MD, Brian P. MD, John A. MPH, W.R. MD, MEd, Zeljko MD, PhD, Leah MS, Michael MD, Mitchell S. MD, Cary N. MD, Thomas J. MD, Judd W. MD,